Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus
- 19 February 2005
- journal article
- research article
- Published by Elsevier BV in Antiviral Research
- Vol. 66 (2-3), 159-163
- https://doi.org/10.1016/j.antiviral.2005.01.003
Abstract
The activity of inosine-5′-monophosphate dehydrogenase (IMPDH) inhibitors, mizoribine and ribavirin, against severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) was determined by plaque reduction and yield reduction assays. Mizoribine and ribavirin selectively inhibited replication of SARS-CoV. The 50% inhibitory concentration (IC50) of mizoribine for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, as determined by plaque reduction was 3.5 μg/ml and 16 μg/ml, respectively, and the IC50 of ribavirin for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849 was 20 μg/ml and 80 μg/ml, while the 50% cytotoxic concentration of mizoribine and ribavirin for Vero E6 cells exceeded 200 μg/ml. In a yield reduction assay, mizoribine (10 μg/ml) and ribavirin (40 μg/ml) inhibited the replication of SARS-CoV and reduced the infectious SARS-CoV titers to one-tenth or less. Mizoribine inhibited replication of SARS-CoV more strongly than ribavirin. However, neither drug could completely inhibit replication of SARS-CoV even at concentrations up to 100 μg/ml.Keywords
This publication has 32 references indexed in Scilit:
- Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)Virology, 2004
- Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by NiclosamideAntimicrobial Agents and Chemotherapy, 2004
- Interferon-β 1a and SARS Coronavirus ReplicationEmerging Infectious Diseases, 2004
- Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR ChinaJournal of Medical Microbiology, 2003
- A Major Outbreak of Severe Acute Respiratory Syndrome in Hong KongNew England Journal of Medicine, 2003
- Recent progress in antiviral chemotherapy for respiratory syncytial virus infectionsExpert Opinion on Investigational Drugs, 2000
- The broad spectrum antiviral agent ribavirin inhibits capping of mRNABiochemical and Biophysical Research Communications, 1979
- Virazole (1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide; A cytostatic agentBiochemical Pharmacology, 1977
- Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin TriphosphateAntimicrobial Agents and Chemotherapy, 1977
- CONSEQUENCES OF INHIBITION OF GUANINE NUCLEOTIDE SYNTHESIS BY MYCOPHENOLIC-ACID AND VIRAZOLE1977